| EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma AD Durbin, T Wang, VK Wimalasena, MW Zimmerman, D Li, NV Dharia, ... Cancer discovery 12 (3), 730-751, 2022 | 105 | 2022 |
| Using chemical epigenetics to target cancer VK Wimalasena, T Wang, LH Sigua, AD Durbin, J Qi Molecular cell 78 (6), 1086-1095, 2020 | 49 | 2020 |
| Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders YD Li, MW Ma, MM Hassan, M Hunkeler, M Teng, K Puvar, R Lumpkin, ... BioRxiv, 2023 | 40 | 2023 |
| BAF complex maintains glioma stem cells in pediatric H3K27M glioma E Panditharatna, JG Marques, T Wang, MC Trissal, I Liu, L Jiang, A Beck, ... Cancer discovery 12 (12), 2880-2905, 2022 | 38 | 2022 |
| Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors A Muthengi, VK Wimalasena, HO Yosief, MJ Bikowitz, LH Sigua, T Wang, ... Journal of medicinal chemistry 64 (9), 5787-5801, 2021 | 26 | 2021 |
| Peptide-based PROTAC: the predator of pathological proteins YZ Au, T Wang, LH Sigua, J Qi Cell chemical biology 27 (6), 637-639, 2020 | 26 | 2020 |
| Template-assisted covalent modification underlies activity of covalent molecular glues YD Li, MW Ma, MM Hassan, M Hunkeler, M Teng, K Puvar, JC Rutter, ... Nature Chemical Biology, 1-10, 2024 | 11 | 2024 |
| BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming K Sevinç, GG Sevinç, AD Cavga, M Philpott, S Kelekçi, H Can, AP Cribbs, ... Stem cell reports 17 (12), 2629-2642, 2022 | 9 | 2022 |
| Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition NAM Shendy, M Bikowitz, LH Sigua, Y Zhang, A Mercier, Y Khashana, ... Nature Communications 15 (1), 3483, 2024 | 2 | 2024 |
| Dihydropyridine lactam analogs targeting BET bromodomains J Jiang, LH Sigua, A Chan, P Kalra, WCK Pomerantz, E Schönbrunn, J Qi, ... ChemMedChem 17 (1), e202100407, 2022 | 2 | 2022 |
| Targeting the Oncofetal Transcription Factor Protein SALL4 in Cancer By a Non-IMiD Degrader KAL Vu, K Kumari, BH Liu, C Gao, F Li, JP Tang, D Maddalo, X Tian, ... Blood 142, 7144, 2023 | 1 | 2023 |
| SALL4B, not targeted by IMiD, is important for SALL4-mediated tumorigenesis KA L. Vu, K Kumari, BH Liu, C Gao, F Li, JP Tang, D Maddalo, DS Auld, ... bioRxiv, 2023.07. 07.548071, 2023 | 1 | 2023 |
| Arginine methyltransferase 5 (prmt5) degraders and uses thereof J Qi, L Wu, PM Park, LH Sigua US Patent App. 17/917,075, 2023 | 1 | 2023 |
| 1, 4‐Dihydropyridinebutyrolactone‐derived ring‐opened ester and amide analogs targeting BET bromodomains J Jiang, PL Zhao, LH Sigua, A Chan, E Schönbrunn, J Qi, GI Georg Archiv der Pharmazie 355 (11), 2200288, 2022 | 1 | 2022 |
| BRD9-containing non-canonical BAF complexes safeguard cell identity and prevent reprogramming K Sevinç, GG Sevinç, AD Cavga, M Philpott, S Kelekçi, H Can, AP Cribbs, ... bioRxiv, 2021.05. 27.445940, 2021 | 1 | 2021 |
| A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development AT Fan, GE Gadbois, HT Huang, C Chaudhry, J Jiang, LH Sigua, ... Angewandte Chemie 137 (5), e202417272, 2025 | | 2025 |
| SMALL MOLECULES FOR DOT1L DEGRADATION AND USES THEREOF J Qi, LH Sigua US Patent App. 18/699,348, 2024 | | 2024 |
| Template-assisted covalent modification of DCAF16 enables BRD4 molecular glue degraders YD Li, MW Ma, MM Hassan, K Puvar, M Teng, B Sandoval, R Lumpkin, ... Cancer Research 83 (7_Supplement), 3424-3424, 2023 | | 2023 |
| Novel Therapeutic Approaches to Target Chromatin/Transcription Targeting EP300 and CBP for therapeutic benefit in pediatric solid tumors. AD Durbin, N Shendy, A Mercier, Y Zhang, MJ Bikowitz, LH Sigua, ... CANCER RESEARCH 82 (23), 2022 | | 2022 |
| Abstract PR005: Targeting EP300 and CBP for therapeutic benefit in pediatric solid tumors AD Durbin, N Shendy, A Mercier, Y Zhang, MJ Bikowitz, LH Sigua, ... Cancer Research 82 (23_Supplement_2), PR005-PR005, 2022 | | 2022 |
